Chengdu Olymvax Biopharmaceuticals Inc.’s Net Profit Dropped 26.7% in First Half of 2022

Chengdu Olymvax Biopharmaceuticals Inc. (成都欧林生物科技股份有限公司) (688319.SH) reported a net profit of 31 million yuan in the first half of 2022, down 26.7% year-on-year.

Meanwhile, the company posted 232.7 million yuan in revenue, up 37.6% year-on-year.

At the end of the reporting period, it had 1.3 billion yuan in total assets and 425.6 million yuan in total liabilities, with a liability-to-asset ratio of 32.7%.